AVTX — Avalo Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1534120 ·
Last close
$16.02
Market Cap
$842.10M
52W High
$24.27
52W Low
$12.51
ADV30
2,120,958
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -20,901,000 | -19,630,000 | 99,885,000 | 24,988,000 | 31,565,000 |
| Dec 2025 | 59,000 | 59,000 | -19,742,000 | -13,720,000 | 116,458,000 | 15,858,000 | 33,409,000 |
| Sep 2025 | 0 | 0 | -19,198,000 | -30,625,000 | 125,100,000 | 26,963,000 | 33,553,000 |
| Jun 2025 | 0 | 0 | -19,316,000 | -20,765,000 | 126,583,000 | 42,290,000 | 22,009,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,458,000
Investing CF
$-81,720,000
Financing CF
$14,587,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.19
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-448,522,000
Inventory
—
Receivables
$611,000
ST Investments
$82,478,000
EBIT TTM
$-72,925,000
Pretax Income TTM
$-78,094,000
Interest Exp TTM
—
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$59,000
EBITDA
$-78,931,000
Free Cash Flow
$-23,247,124
Enterprise Value
$777,782,080
Total Cash
$81,993,000
Total Debt
$328,000
Shares Out
52,565,572
Trailing EPS
$-5.57
Book Value
$4.49
ROE
-88.8%
ROA
-41.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 59,000 | -72,925,000 | -78,259,000 | 116,458,000 | 33,409,000 | — | -51,458,000 |
| Dec 2024 | 441,000 | -40,871,000 | -35,129,000 | 150,732,000 | 17,700,000 | — | -49,056,000 |
| Dec 2023 | 1,924,000 | -23,444,000 | -31,544,000 | 20,993,000 | 13,689,000 | — | -30,680,000 |
| Dec 2022 | 18,051,000 | -37,440,000 | -41,658,000 | 33,367,000 | 44,282,000 | — | -26,751,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$249,000
NetIncome TTM
$23,037,000
OpCashFlow TTM
$0
Assets (Latest)
$150,732,000
Forward EPS
$-2.87
Max Pain — expiry 2026-06-18
max pain strike: $12.50 · spot: $16.02 · call oi: 29,712 · put oi: 11,181
Expected Move to 2026-06-18:
±$2.48
(15.45%) —
implied range
$13.55 –
$18.50
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OMER | OMEROS CORP | $843.17M | $11.65 | — |
| EVMN | Evommune, Inc. | $841.03M | $23.35 | — |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $844.44M | $86.28 | — |
| TBPH | Theravance Biopharma, Inc. | $845.98M | $16.41 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $829.39M | $18.81 | — |
News headlines (Yahoo Finance, 1h cache)
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
2026-05-22 20:01 · Yahoo
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
2026-05-13 11:00 · Yahoo
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
2026-05-06 20:07 · Yahoo
Avalo shares spike on skin drug data; BioNTech to cut staff
2026-05-06 10:30 · Yahoo
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
2026-05-06 03:33 · Yahoo
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-05-05 20:05 · Yahoo
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
2026-05-05 20:01 · Yahoo
Avalo Therapeutics Purchases Optional Milestone Buyout
2026-04-28 11:00 · Yahoo
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
2026-04-06 15:10 · Yahoo
Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth Plans
2026-04-06 12:49 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.